Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions

European Journal of Pharmacology

Volumn 451, Issue 2, 2002, Pages 149-155

  Seegers, Ulrike ^a   Potschka, Heidrun ^a   Löscher, Wolfgang ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Antiepileptic drug; Epilepsy; Multidrug resistance gene; Pharmacoresistance

Indexed keywords

ANTICONVULSIVE AGENT; GLYCOPROTEIN P; PHENOBARBITAL; PHENYTOIN;

AMYGDALOID NUCLEUS; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; DENTATE GYRUS; DRUG EFFECT; ENDOTHELIUM; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LONG TERM EXPOSURE; NONHUMAN; PARENCHYMA; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRIFORM CORTEX; RAT; SUBSTANTIA NIGRA; TEMPORAL LOBE;

ANIMALS; BRAIN; FEMALE; GENE EXPRESSION REGULATION; P-GLYCOPROTEIN; PHENOBARBITAL; PHENYTOIN; RATS; RATS, WISTAR;

EID: 0037072554     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02235-5     Document Type: Article

References (31)

1. Dombrowski S.M., Desai S.Y., Marroni M., Cucullo L., Goodrich K., Bingaman W., Mayberg M.R., Bengez L., Janigro D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia. 42:2001;1501-1506.
2. Fardel O., Payen L., Courtois A., Vernhet L., Lecureur V. Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology. 167:2001;37-46.
3. Frey H.-H. Experimental evidence for the development of tolerance to anticonvulsant drug effects. Frey H.-H., Fröscher W., Koella W.P., Meinardi H. Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs. 1986;7-16 Raven Press, New York.
4. Fromm M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38:2000;69-74.
5. Golden P.L., Pardridge W.M. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. Cell. Mol. Neurobiol. 20:2000;165-181.
6. Huber J.D., Egleton R.D., Davis T.P. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 24:2001;719-725.
7. Jette L., Tetu B., Beliveau R. High levels of P-glycoprotein detected in isolated brain capillaries. Biochim. Biophys. Acta. 1150:1993;147-154.
8. Lee G., Dallas S., Hong M., Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53:2001;569-596.
9. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40:1997;S3-S8. (Suppl.).
10. Löscher W., Hönack D. Comparison of the anticonvulsant efficacy of primidone and phenobarbital during chronic treatment of amygdala-kindled rats. Eur. J. Pharmacol. 162:1989;309-322.
11. Löscher W., Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301:2002;7-14.
12. Michalets E.L. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 18:1998;84-112.
13. Pardridge W.M. Blood-brain barrier biology and methodology. J. Neurovirology. 5:1999;556-569.
14. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 4th Ed. 1998;Academic Press, Sydney.
15. Potschka H., Löscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia. 42:2001;1231-1240.
16. Regesta G., Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 34:1999;109-122.
17. Rizzi M., Guiso G., Mulé F., Moneta D., Sperk G., Vezzani A., Caccia S. Induction of mdr-1 by limbic seizures in mice: relevance for drug resistance in epilepsy. Abstr.-Soc. Neurosci. 27:2001;553.2.
18. Rundfeldt C., Löscher W. Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala-kindled rats. J. Pharmacol. Exp. Ther. 266:1993;216-223.
19. Runge D., Kohler C., Kostrubsky V.E., Jager D., Lehmann T., Runge D.M., May U., Stolz D.B., Strom S.C., Fleig W.E., Michalopoulos G.K. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem. Biophys. Res. Commun. 273:2000;333-341.
20. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:1996;2517-2524.
21. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:1996;311-318.
22. Seegers U., Potschka H., Löscher W. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia. 43:2002;675-684.
23. Seegers U., Potschka H., Löscher W. Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res. 2002;. (in press).
24. Silverman J.A. Multidrug-resistance transporters. Pharm. Biotechnol. 12:1999;353-386.
25. Silverman J.A., Thorgeirsson S.S. Regulation and function of the multidrug resistance genes in liver. Prog. Liver Dis. 13:1995;101-123.
26. Sisodiya S.M., Lin W.-R., Harding B.N., Squier M.V., Keir G., Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 125:2002;22-31.
27. Tanaka E. Clinically significant pharmacokinetic drug interactions with benzodiazepines. J. Clin. Pharm. Ther. 24:1999;347-355.
28. Tishler D.M., Weinberg K.T., Hinton D.R., Barbaro N., Annett G.M., Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 36:1995;1-6.
29. Volk B., Meyer R.P., von Lintig F., Ibach B., Knoth R. Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Toxicol. Lett. 82-83:1995;655-662.
30. Worboys P.D., Carlile D.J. Implications and consequences of enzyme induction on preclinical and clinical drug development. Xenobiotica. 31:2001;539-556.
31. Zhang L., Ong W.Y., Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp. Brain Res. 126:1999;509-516.